Evidence map›Paper›PMID 41858425›Full record

ReviewNeuropsychiatric disease and treatment2026

Epigenetic Changes in Alzheimer's Disease and Interventions for Therapy.

Mingjing Xu, Lijun Xiong, Zhenjuan Qin, Xinyi Yu, Tao Chen, Xinxin Zhang, Mingyue Jin, Liping Wang, Longqiang Cai, Yuhua Wei and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mingjing Xu *School of Public Health, Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Lijun Xiong *College of Biotechnology, Guilin Medical University, Guilin, Guangxi, People's Republic of China.
Zhenjuan Qin *Key Laboratory of Mental Disorders and Prevention, Guangxi Zhuang Autonomous Region Brain Hospital, Liuzhou, Guangxi, People's Republic of China.
Xinyi Yu *School of Public Health, Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi, People's Republic of China.
Tao Chen *School of Public Health, Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi, People's Republic of China.
Xinxin Zhang *School of Public Health, Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Mingyue Jin *Department of Genetic Disease Research, Osaka Metropolitan University, Osaka, Japan.
Liping Wang *College of Biotechnology, Guilin Medical University, Guilin, Guangxi, People's Republic of China.
Longqiang Cai *Key Laboratory of Mental Disorders and Prevention, Guangxi Zhuang Autonomous Region Brain Hospital, Liuzhou, Guangxi, People's Republic of China.
Yuhua Wei *Key Laboratory of Mental Disorders and Prevention, Guangxi Zhuang Autonomous Region Brain Hospital, Liuzhou, Guangxi, People's Republic of China.
Huihua Liu *Key Laboratory of Mental Disorders and Prevention, Guangxi Zhuang Autonomous Region Brain Hospital, Liuzhou, Guangxi, People's Republic of China.
Chengqiang WangCollege of Biotechnology, Guilin Medical University, Guilin, Guangxi, People's Republic of China.
Huilin Hu *Key Laboratory of Mental Disorders and Prevention, Guangxi Zhuang Autonomous Region Brain Hospital, Liuzhou, Guangxi, People's Republic of China.
Zhenyou ZouSchool of Public Health, Guangxi Medical University, Nanning, Guangxi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the ageing of society, the number of Alzheimer's disease (AD) patients has increased rapidly, imposing a heavy burden on families and society. This article reviews the causes of AD, particularly the epigenetic changes associated with AD, including DNA methylation, histone modifications, and noncoding RNA changes. The development of diagnostic reagents based on biomarkers specific to epigenetic changes and attempts to intervene in adverse epigenetic factor changes in AD for the treatment of AD are discussed. This review contributes to a better understanding of the relationship between epigenetics and AD and provides guidance for exploring diagnostic and therapeutic strategies.

Indexed as

Alzheimer’s diseaseDNA methylationepigeneticshistone modificationnoncoding RNA

Identifiers

PMID41858425
PMCPMC12998893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.